Microsatellite instability and other molecular markers: how usefulare they? Pr Frédéric Bibeau, MD, PhD Pathology Department CHU de Caen France
|
|
- Magdalene Ford
- 5 years ago
- Views:
Transcription
1 Microsatellite instability and other molecular markers: how usefulare they? Pr Frédéric Bibeau, MD, PhD Pathology Department CHU de Caen France
2 Content - Colorectal cancer context - CRC molecular classification - Diagnostic value - Prognostic value - Therapeutic value - Perspectives - Conclusion
3 Content - Colorectal cancer context - CRC molecular classification - Diagnostic value - Prognostic value - Therapeutic value - Perspectives - Conclusion
4 ptnm CRC classification MUCOSA Muscularis Muscosae --> SUB-MUCOSA MUSCULARIS SUB-SEROSA --> SEROSA --> pt Tis T1 T2 T3 T4 pn pm N0 : no positive lymph node (LN) N1 : 3 positive LN N2 : 4 positive LN M0 : No distant metastasis M1 : Distant metastasis TNM UICC th Classification Organe infiltration and / or visceral peritoneal perforation
5 Early CRC treatment N+ Stage III Chemotherapy (FOLFOX, 5-FU) pt3-4 N0 Stage II No chemotherapy But rate of relapses: 20% Need for additionnal prognostic factors
6 Metastatic CRC treatment 6 patients/10 Chemotherapy: 5FU/oxaliplatin/irinotecan Targeted therapies: -Cetuximab(Erbitux )(IgG1) -Panitumumab(Vectibix )(IgG2) -Bevacizumab (Avastin )(IgG1) Aflibercept(Zaltrap ), Regorafenib(Stivarga ) Need for predictive factors Anti-EGFR Epidermal Growth Factor Receptor Anti-VEGF Vascular Endothelial Growth Fractor
7 CRC context Sporadic (majority of cases) Hereditary (6 % of cases) Screening tools Optimal management
8 Content - Colorectal cancer context - CRC molecular classification - Diagnostic value - Prognostic value - Therapeutic value - Perspectives - Conclusion
9 CRC tumour progression Aberrant crypts small polype advanced polyp avancé cancer metastases
10 Voies CRC d oncogenèse carcinogenesis CCR CIN pathway CIMP pathway MSI pathway Chromosomic Instabilty CpG Island Methylator Phenotype Epigenetic instability MicroSatellite Instabilty % 20 % %
11 Chromosomic instability Genomic comparative hybridization(gch array) Aneuploidy Chromosomiclosses/gains Deletions Loss of heterozygocity Mutations: RAS, TP53,.. Amplifications
12 Epigenetic instability CIMP: CpG Island Methylator Phenotype(tumour suppressor genes) Genes methylation: hmhl1, P16, MGMT BRAFmutation
13 Microsatellite instability Normal DNA MSI tumour Loss or gain of nucleotides (ou soustraction) Diploidy No /or few lossof heterozygocity
14 4 proteins for DNA reparation MisMatch Repair system (MMR)
15 DeficientMMR system 4 proteins for DNA reparation Altered apoptose, cell cycle related gened MSI CRC carcinogenesis
16 Terminology MSI (microsatellite instable) MSS (microsatellite stable) dmmr (deficient mismatch repair) pmmr (proficient mismatch repair) PhenotypeRER+ (Replication Error+) Phenotype RER- (Replication Error-)
17 Immunohistochemistry Stable tumour(mss): 4 MMR proteins expressed
18 Immunohistochemistry Instable tumour(msi): extinction of MMR proteins Loss of hml1 hmsh2 + Negative tumour Positive tumour hmsh6 + Parallel loss of PMS2 personna l casel F. Bibeau *MisMatch Repair
19 Molecular profile Microsatellite Instability Normal DNA MSI tumour Nucleotides (ou soustraction) Lossor gain
20 CRC molecular classification Chromosomic instability Epigenetic instability Microsatellite instability CIN pathway CIMP pathway MSI pathway % 20 % % Conventionnal carcinoma Serrated tumours Cancer of the elderly Lynch syndrome Lieberkühnian Serrated Médullary/ lymphocytes
21 Content - Colorectal cancer context - CRC molecular classifications - Diagnostic value - Prognostic value - Therapeutic value - Perspectives - Conclusion
22 Lynch syndrome screening Autosomicdominant transmission MLH1 MHS2 MSH6 PMS2 Germlinemutation Constant MSI EarlyonsetCRC Multiple locations Familial context Othercancers
23 Lynch syndrome screening Othercancers Colorectal Urinarytract Small bowel Endometrium Lynch syndrome spectrum HNPCC: Hereditary Non Polyposis Colorectal Cancer Cancer risk: 75% CCR, 50% endometrium, 15% others
24 Lynch syndrome screening MLH1 MSH2 MSH6 PMS2 Germilemutation Time consuming Highly specialized laboratories Constant MSI
25 Lynch syndrome screening MLH1 MSH2 MSH6 PMS2 Germilemutation Time consuming Highly specialized laboratories Constant MSI DNA Mutation of the corresponding gene RNA PROTEINS
26 Lynch syndrome screening CRC < 60 ans Personal CRC history CRC familial context MSI + Clinical, endoscopic, and US (si woman) follow-up + Familial investigation Lynch diagnosis Oncogenetics team consultation Germile mutation determination Prophylactic surgery
27 Microsatellite instability context MSI and hmlh1 loss Sporadic cancer (15%) Hypermethylation MLH1 promotor BRAF mutation Lynch syndrome (2%) Absent Absent Elderly patient Young patient
28 Content - Colorectal cancer context - CRC molecular classifications - Diagnostic value - Prognostic value - Therapeutic value - Perspectives - Conclusion
29 Identification of favorable stage II CRC Normal DNA MSI MSI tumour Loss or gain of nucleotides No adjuvant chemotherapy(5-fu)
30 Caracterization of high risk CRC stage II Perforation Occlusion pt4 Lymphnode< 12 Poorly differenciated tumour Venous/lymphaticInvasion Perineural invasion MSS Adjuvant chemotherapy: to be discussed (5-FU)
31 Immune infiltration assessement: Immunoscore?
32 Caracterization of agressive stage III CRC MSS KRAS mut. BRAFmut. Intensifiedchemotherapy: clinicaltrials Stratification accordingmutations? *Taieb et al JAMA Oncol 2016
33 Identification of agressive stage IV CRC MSS KRAS mut. BRAFmut. Metastatic setting Intensified chemotherapy: FOLFIRINOX+ Bevacizumab(BRAF mut.) Ongoing clinical trials
34 Content - Colorectal cancer context - CRC molecular classifications - Diagnostic value - Prognostic value - Therapeutic value - Perspectives - Conclusion
35 Anti-EGFR targeted therapies KRAS mutations = marker of resistance Anti-EGFR antibodies Cetuximab Panitumumab Chemotherapy Radiotherapy Motility Metastases Cell cycle activation Growth Angiogenesis
36 Résistance: mutations KRAS Normal différenciation, proliferation and growth abnormal différenciation, proliferation and growth Adapté de Van Krieken et al. Virchows 2008;453:
37 Resistance: RAS mutations Mutations! KRAS EXON 1 EXON 2 EXON 3 EXON N/A 3,8% 5,8% NRAS EXON 1 EXON 2 EXON 3 EXON ,5% 4,1% 0% BRAF EXON 1 EXON 15 EXON % Douillard et al. N Engl J Med. 2013;369:
38 Recommendations RAS testing mandatory before anti-egfr therapy on Primary CRC Metastasis Or
39 Molecular techniques
40 Quality of the pre-analytique step Selection Macrodissection Mutation?
41 Quality of the pre-analytique step Use the pretreatment biopsy
42 Complex molecular profile but targetable alterations Amplifications: 2,5% Mutations: 1,9% ALK/ROS/NTRK1,2,3Fusion (<1%) HER-2 FGFRAmplification (<1%) RAS and BRAFWT 40% MSI 5% Mutation KRASexon 2 RAS mut 50% BRCA2 mutation BRAF 10% Mut KRAS ex 3, 4 Mut NRAS Rankin Oncologist 2016
43 Immunotherapy MSI CRC : immunogenic tumour Metastatic MSI CRC Crohn like reaction Immune escape Lymphocytic infiltrate
44 MSI CRC : immunogenic tumour Immunotherapy Check-points immunity inhibitors T lymphocyte receptor Antigen Immune enhancement Tumor cell T lymphocyte receptor Antigen PD1 inhibitor Tumor cell Response rate: 90% (anti-pd1 pembrolizumab) PDL1 inhibitor Le DT et al. N Eng J Med 2015;372:
45 Immunotherapy Anti-PDL-1 treatment: overall survival CCR MSI CCR MSS Mois Selection of patients based on MSI status
46 Content - Colorectal cancer context - CRC molecular classifications - Diagnostic value - Prognostic value - Therapeutic value - Perspectives - Conclusion
47 RAS and BRAF mutationnal status determination Circulating tumour DNA?
48 Molecular profile Signatures CIT* Carte Identité Tumeurs dm CMS** Consensus Molecular signature Poor pronosis Addition of immune signature? *Marisa et al. Plos One 2016, * * Guinney Nature Med 2015 Adapté de Pagès et al., New Engl J Med 2005
49 Profil moléculaire Signatures Prediction of response to FOLFIRI, Cetuximab? Reliable on fixed tissue? Reliable by using immunohistochimistry? *Marisa et al. Plos One 2016, Guinney Nature Med 2015
50 Quality control
51 Quality control
52 Quality control
53 Content - Colorectal cancer context - CRC molecular classification - Diagnostic value - Prognostic value - Therapeutic value - Perspectives - Conclusion
54 Molecular CRC classification- Useful biomarkers CIN pathway % CIMP pathway MSI pathway 20 % % Conventional carcinoma Serrated tumours Cancer of the elderly Lynch syndrome RAS mutation Anti-EGFR resistance (predictive factor) BRAF mutation Pronostic factor Lynch diagnosis MSI Pronostic No 5-FU efficacy Anti-PD1 efficacy
55 Back-Up
56 Complex molecular profile but targetable alterations Amplifications: 2,5% Mutations: 1,9% HER-2 anti-egfr resistance? Raghac ASCO 2016 RAS and BRAFWT Mutation KRASexon 2 anti-her2 Targeted therapies? Trastuzumab + lapatinib (HERACLES) Trastuzumab + pertuzumab Sartore-Bianchi Lancet Oncol 2016 Hurwitz ASCO GI % BRAF 10% MSI 5% Mut KRAS ex 3, 4 Mut NRAS RAS mut 50% SPECTAcolor: Folprecht ESMO 2016, abst 4580
57 Complex molecular profile but targetable alterations Fusion ALK/ROS/NTRK1,2,3 (<1%) HER-2 Entrectinib De BraudASCO 2015 Sartore-Bianchi JNCI 2016 RAS and BRAFWT 40% MSI 5% Mutation KRASexon 2 RAS mut 50% BRAF 10% Mut KRAS ex 3, 4 Mut NRAS Rankin Oncologist 2016
58
Microsatellite instability and other molecular markers: how useful are they?
Microsatellite instability and other molecular markers: how useful are they? Pr Frédéric Bibeau, MD, PhD Head, Pathology department CHU de Caen, Normandy University, France ESMO preceptorship, Barcelona,
More informationEarly colorectal cancer Quality and rules for a good pathology report Histoprognostic factors
Early colorectal cancer Quality and rules for a good pathology report Histoprognostic factors Frédéric Bibeau, MD, PhD Pathology department Biopathology unit Institut du Cancer de Montpellier France Quality
More informationDevelopment of Carcinoma Pathways
The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019
More informationSerrated Polyps and a Classification of Colorectal Cancer
Serrated Polyps and a Classification of Colorectal Cancer Ian Chandler June 2011 Structure Serrated polyps and cancer Molecular biology The Jass classification The familiar but oversimplified Vogelsteingram
More informationHisto-prognostic factors what histopathology has to offer for clinical decision making
Histo-prognostic factors what histopathology has to offer for clinical decision making Daniela E. Aust Institute for Pathology, University Hospital Dresden, Germany Center for Molecular Tumor Diagnostics
More informationEarly colorectal cancer Quality and rules for a good pathology report Histoprognostic factors
Early colorectal cancer Quality and rules for a good pathology report Histoprognostic factors Pr Frédéric Bibeau, MD, PhD Head, Pathology department CHU de Caen, Normandy University, France ESMO preceptorship,
More informationINMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO. CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS?
INMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS? V. Alonso Servicio de Oncologia Medica H. U. Miguel Servet Zaragoza MSI-H mcrc Clinical and Pathological
More informationMolecular subtyping: how useful is it?
Molecular subtyping: how useful is it? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Center for Molecular Tumor Diagnostics at the NCT-Partner Site Dresden CMTD Disclosure
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationColorectal cancer Chapelle, J Clin Oncol, 2010
Colorectal cancer Chapelle, J Clin Oncol, 2010 Early-Stage Colorectal cancer: Microsatellite instability, multigene assay & emerging molecular strategy Asit Paul, MD, PhD 11/24/15 Mr. X: A 50 yo asymptomatic
More informationMSI and other molecular markers: how useful are they? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany
MSI and other molecular markers: how useful are they? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Disclosure slide I Member of advisory boards for AMGEN, ROCHE I Speaker
More informationMolecular markers in colorectal cancer. Wolfram Jochum
Molecular markers in colorectal cancer Wolfram Jochum Biomarkers in cancer Patient characteristics Tumor tissue Normal cells Serum Body fluids Predisposition Diagnostic marker Specific diagnosis Prognostic
More informationDisclosure slide I Member of advisory board for AMGEN, ROCHE, BOEHRINGER I Speaker honoraria from FALK Pharma, Pfizer, Lilly and ROCHE I Third party f
Early (and not so early) colorectal cancer: The pathologist s point of view Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Disclosure slide I Member of advisory board for
More informationColorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann
Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell
More informationEarly (and not so early) colorectal cancer: The pathologist s point of view
Early (and not so early) colorectal cancer: The pathologist s point of view Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Disclosure slide I Member of advisory board for
More informationColon Cancer Update Christie J. Hilton, DO
POMA Winter Conference Christie Hilton DO Medical Oncology January 2018 None Colon Cancer Numbers Screening (brief update) Practice changing updates in colon cancer MSI Testing Immunotherapy in Colon Cancer
More informationXXV Corso Nazionale TSLB: evoluzione o ri(e)voluzione?
XXV Corso Nazionale TSLB: evoluzione o ri(e)voluzione? Marcatori predittivi di efficacia nel carcinoma del colon: DESTRO verso SINISTRO conta? Dott. Matteo Clavarezza S.C. Oncologia Medica RAS metastatic
More informationAdjuvant/neoadjuvant systemic treatment of colorectal cancer
5th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology Belgrade, June 19 th 2018 Adjuvant/neoadjuvant systemic treatment of colorectal cancer Carlotta Antoniotti Polo Oncologico
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationNovel Molecularly Targeted Therapies and Biomarkers in Advanced Colorectal Cancer. Objectives
Novel Molecularly Targeted Therapies and Biomarkers in Advanced Colorectal Cancer Michael S. Lee, MD Assistant Professor of Medicine University of North Carolina Objectives Discuss important clinicopathologic
More informationColon Cancer and Hereditary Cancer Syndromes
Colon Cancer and Hereditary Cancer Syndromes Gisela Keller Institute of Pathology Technische Universität München gisela.keller@lrz.tum.de Colon Cancer and Hereditary Cancer Syndromes epidemiology models
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationHigh risk stage II colon cancer
High risk stage II colon cancer Joel Gingerich, MD, FRCPC Assistant Professor Medical Oncologist University of Manitoba CancerCare Manitoba Disclaimer No conflict of interests 16 October 2010 Overview
More informationBRAF Testing In The Elderly: Same As in Younger Patients?
EGFR, K-RAS, K BRAF Testing In The Elderly: Same As in Younger Patients? Nadine Jackson McCleary MD MPH Gastrointestinal Oncology Dana-Farber/Harvard Cancer Care Boston, MA, USA Outline Colorectal cancer
More informationMolecular biology of colorectal cancer
Molecular biology of colorectal cancer Phil Quirke Yorkshire Cancer Research Centenary Professor of Pathology University of Leeds, UK Rapid pace of molecular change Sequencing changes 2012 1,000 genomes
More informationADVANCES IN COLON CANCER
ADVANCES IN COLON CANCER Peter T. Silberstein, M.D., FACP Professor, Creighton University Chief Hematology/Oncology UNIVERSAL SCREENING FOR LYNCH SYNDROME OF ALL PATIENTS WITH COLON CANCER ADOPTED BY CHI
More informationObjectives. Briefly summarize the current state of colorectal cancer
Disclaimer I do not have any financial conflicts to disclose. I will not be promoting any service or product. This presentation is not meant to offer medical advice and is not intended to establish a standard
More informationMarcatori biomolecolari dei carcinomi del colon-retto sporadici ed ereditari
Marcatori biomolecolari dei carcinomi del colon-retto sporadici ed ereditari Milo Frattini XII Congresso AIFEG Villa Cagnola - Gazzada Schianno (VA) 16/17.10.2014 APC β-catenina APC Met (p16) Models of
More informationColorectal Carcinoma Reporting in 2009
Colorectal Carcinoma Reporting in 2009 Overview Colorectal carcinoma- new and confusing AJCC TNM issues Wendy L. Frankel, M.D. Vice-Chair and Director of AP Department of Pathology The Ohio State University
More informationAnatomic Molecular Pathology: An Emerging Field
Anatomic Molecular Pathology: An Emerging Field Antonia R. Sepulveda M.D., Ph.D. University of Pennsylvania asepu@mail.med.upenn.edu 2008 ASIP Annual Meeting Anatomic pathology (U.S.) is a medical specialty
More informationM. Azzam Kayasseh,Dubai,UAE
Thanks A Lot Prof. Linda + Prof. Ernst #drkayasseh_crc_rsm #WEO_CRCSC #UEGW17 @dubaiendoscopyforum @drkayasseh.care.to.cure Twenty World Areas Age-Standardized CRC Incidence Rates by Sex GLOBOCAN 2008
More informationWhat Pathology can tell us in the approach of localized colorectal cancer
What Pathology can tell us in the approach of localized colorectal cancer A/Prof Tony Lim Kiat Hon Department of Anatomical Pathology Singapore General Hospital ESMO 2017 Singapore Nov 1 2 Do we still
More informationGuidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer
Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer Start date: May 2015 Review date: April 2018 1 Background Mismatch repair (MMR) deficiency is seen in approximately 15%
More informationMETASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD
METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health Technology Appraisal Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
More informationColorectal adenocarcinoma leading cancer in developed countries In US, annual deaths due to colorectal adenocarcinoma 57,000.
Colonic Neoplasia Remotti Colorectal adenocarcinoma leading cancer in developed countries In US, annual incidence of colorectal adenocarcinoma 150,000. In US, annual deaths due to colorectal adenocarcinoma
More informationColorectal cancer: pathology
UK NEQAS for Molecular Pathology Colorectal cancer: pathology Nick West Pathology & Tumour Biology May 2013 Colorectal cancer (CRC) 40,695 new cases in 2010 15,708 deaths Management of CRC Surgery Main
More informationGastric and Colon Cancer. Dr. Andres Wiernik 2017
Gastric and Colon Cancer Dr. Andres Wiernik 2017 GASTRIC CANCER Gastric Cancer Classification Epidemiology General principles of Management 25% GE Junction Gastric Cancer 75% Gastric Cancer Epidemiology
More informationThird Line and Beyond: Management of Refractory Colorectal Cancer
Third Line and Beyond: Management of Refractory Colorectal Cancer George A. Fisher MD PhD Stanford University 1 Overview Defining the chemo refractory and intolerant Agents approved in 3 rd line setting
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationTHE CROSSROADS: Drug Development, Biomarkers, and Colorectal Cancer
THE CROSSROADS: Drug Development, Biomarkers, and Colorectal Cancer SANJAY GOEL, M.D., M.S. PROFESSOR OF MEDICINE ALBERT EINSTEIN COLLEGE OF MEDICINE MONTEFIORE MEDICAL CENTER DEPT. OF ONCOLOGY JUN 22,
More informationIntroduction. Why Do MSI/MMR Analysis?
Clinical Significance Of MSI, KRAS, & EGFR Pathway In Colorectal Carcinoma UCSF & Stanford Current Issues In Anatomic Pathology Introduction Microsatellite instability and mismatch repair protein deficiency
More informationLa genetica del carcinoma colo-rettale
La genetica del carcinoma colo-rettale Ivana Cataldo Ospedale Ca Foncello, Treviso ARC-NET Centro di Ricerca Applicata sul Cancro AOUI, Verona OUTLINE What s new in colorectal cancer? Pathological Markers
More informationTreatment of Advanced Colorectal Cancer
Treatment of Advanced Colorectal Cancer Alexis D. Leal, M.D. Assistant Professor, GI Medical Oncology University of Colorado Cancer Center Disclosures None Objectives Review the basics of advanced colorectal
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer January 2015 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationColorectal Cancer - Working in Partnership. David Baty Genetics, Ninewells Hospital
Colorectal Cancer - Working in Partnership David Baty Genetics, Ninewells Hospital Genetics and Pathology National initiatives Colorectal cancer Inherited CRC Sporadic CRC The Liquid Biopsy The future?
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer March 2017 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationGENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By. Magnitude of the Problem. Magnitude of the Problem. Cardinal Features of Lynch Syndrome
GENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By HENRY T. LYNCH, M.D. 1 Could this be hereditary Colon Cancer 4 Creighton University School of Medicine Omaha, Nebraska Magnitude of the Problem Annual
More informationColorectal Cancer in the Coming Years: What Can We Expect?
Colorectal Cancer in the Coming Years: What Can We Expect? Clara Montagut, MD, PhD Hospital Universitari del Mar, Barcelona, Spain Memorial Sloan Kettering Cancer Center, New York, United States What Are
More informationMolecular Diagnosis for Colorectal Cancer Patients
Molecular Diagnosis for Colorectal Cancer Patients Antonia R. Sepulveda MD, PhD, FCAP October, 20, 2010 www.cap.org Welcome to the PHC Webinar Series This talk on The Molecular Diagnosis for Colorectal
More informationColorectal Cancer: Lumping or Splitting? Jimmy J. Hwang, MD FACP Levine Cancer Institute Carolinas HealthCare System Charlotte, NC
Colorectal Cancer: Lumping or Splitting? Jimmy J. Hwang, MD FACP Levine Cancer Institute Carolinas HealthCare System Charlotte, NC 2 Epidemiology Colorectal Cancer is the 2 nd Leading Cause of Cancer-related
More informationB Base excision repair, in MUTYH-associated polyposis and colorectal cancer, BRAF testing, for hereditary colorectal cancer, 696
Index Note: Page numbers of article titles are in boldface type. A Adenomatous polyposis, familial. See Familial adenomatous polyposis. Anal anastomosis, ileal-pouch, proctocolectomy with, in FAP, 591
More informationTumorNext-Lynch. genetic testing for hereditary colorectal or uterine cancer
TumorNet-Lynch genetic testing for hereditary colorectal or uterine cancer What Are the Causes of Hereditary Colorectal Cancer? sporadic 70% familial 20% hereditary 10% Lynch syndrome, up to 4% Familial
More informationCurrent Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors)
Current Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors) Kael Mikesell, DO McKay-Dee Hospital May 14, 2015 Outline Update to DNA Testing
More informationNational Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant Reporting Period July 1, 2012 June 30, 2013 Formula Grant Overview The National Surgical
More informationADJUVANT CHEMOTHERAPY...
Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED
More informationGenetic testing all you need to know
Genetic testing all you need to know Sue Clark Consultant Colorectal Surgeon, St Mark s Hospital, London, UK. Colorectal cancer Familial 33% Polyposis syndromes
More informationColorectal Cancer Structured Pathology Reporting Proforma DD MM YYYY
Colorectal Cancer Structured Pathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.03). Family name Given name(s) Date of birth DD MM YYYY S1.02 Clinical details
More informationClinical utility of precision medicine in oncology
Clinical utility of precision medicine in oncology Prof. Christophe Le Tourneau, MD, PhD Institut Curie Paris & Saint-Cloud France Head, Department of Drug Development and Innovation (D 3 i) INSERM U900
More informationColorectal cancer molecular biology moves into clinical practice
1 Department of Laboratory Medicine, University of Washington, Washington, USA 2 Clinical Research Division, Fred Hutchison Cancer Research Center, Washington, USA 3 Department of Medicine, University
More informationAgenda 8:30 AM. Jennifer L. Hunt
Agenda Topic Introduction Terence J. Colgan Jennifer L. Hunt Time 8:30 AM Pre-analytic Variables in Molecular Testing Philip A. Branton 8:40 AM Carcinoma of Unknown Primary Site Is Gene Expression Profiling
More informationGenetic Modifiers of Chemotherapy for Colorectal Cancer
Genetic Modifiers of Chemotherapy for Colorectal Cancer September 27, 2011 John M. Carethers, M.D. Professor of Internal Medicine University of Michigan 1,233,700 cases/year Worldwide ~146,000 cases/year
More informationADVANCES IN COLORECTAL CANCERS IS THERE HOPE? Dr Lim Hwee Yong Medical Oncologist
ADVANCES IN COLORECTAL CANCERS IS THERE HOPE? Dr Lim Hwee Yong Medical Oncologist limhweeyong@live.com CRC: Epidemiology in 2012 Third most common cancer diagnosis in US [1] Estimated 143,460 new cases
More informationBiomarkers to optimize treatment selection in colorectal cancer Edwin Pun HUI, MBChB, MD, FRCP (Lond & Edin)
Recent advances in the management of CRC II 2017/12/17 (Sun.) 10:10-11:00 Biomarkers to optimize treatment selection in colorectal cancer Edwin Pun HUI, MBChB, MD, FRCP (Lond & Edin) Department of Clinical
More informationLynch Syndrome. Angie Strang, PGY2
Lynch Syndrome Angie Strang, PGY2 Background Previously hereditary nonpolyposis colorectal cancer Autosomal dominant inherited cancer susceptibility syndrome Caused by defects in the mismatch repair system
More informationReview of the ESMO consensus conference on metastatic CRC Basis strategies ad groups (RAS, BRAF, etc) Michel Ducreux
Review of the ESMO consensus conference on metastatic CRC Basis strategies ad groups (RAS, BRAF, etc) Michel Ducreux 2 ESMO consensus on mcrc 2016 Chairs: Co-Chairs of working groups E Van Cutsem A Sobrero
More informationUpdate on Colorectal Cancer: Integrating the Host Immune Response 3 rd Emirates Surgical Pathology Conference 15 December 2017 Dubai, UAE
Update on Colorectal Cancer: Integrating the Host Immune Response 3 rd Emirates Surgical Pathology Conference 15 December 2017 Dubai, UAE Martine McManus, MD, FCAP Pathology & Laboratory Medicine Institute
More informationThe Whys OAP Annual Meeting CCO Symposium September 20. Immunohistochemical Assessment Dr. Terence Colgan Mount Sinai Hospital, Toronto
Immunohistochemical Assessment of Mismatch Repair Proteins in Endometrial Cancer: The Whys and How Terence J. Colgan, MD Head of Gynaecological Pathology, Mount Sinai Hospital, University of Toronto, Toronto.
More informationImmunotherapy in head and neck cancer and MSI in solid tumors
Immunotherapy in head and neck cancer and MSI in solid tumors Brian Hunis, MD, MBA Associate Medical Director, Memorial Cancer Institute. Hollywood, FL »No disclosures Objectives»Discuss the role of immunology
More informationPost-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationJY Douillard MD, PhD Professor of Medical Oncology
Colorectal Cancer ESMO Preceptorship Program Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer Basic strategy and groups (RASwt/mut, BRAF mut) JY Douillard
More informationBeyond the APC era Alternative pathways to CRC. Jeremy R Jass McGill University
Beyond the APC era Alternative pathways to CRC Jeremy R Jass McGill University Outline Limitations of APC model KRAS and serrated polyps CRC and CpG island methylation Serrated pathway to CRC Fusion pathways
More informationNew Developments in the Treatment of Colorectal Cancer. Jonathan Loree, MD, MS, FRCPC Department of Medical Oncology BC Cancer Vancouver Centre
New Developments in the Treatment of Colorectal Cancer Jonathan Loree, MD, MS, FRCPC Department of Medical Oncology BC Cancer Vancouver Centre Personalized Medicine Currently already part of oncology:
More informationMismatch repair status, inflammation and outcome in patients with primary operable colorectal cancer
Mismatch repair status, inflammation and outcome in patients with primary operable colorectal cancer Park JH, Powell AG, Roxburgh CSD, Richards CH, Horgan PG, McMillan DC, Edwards J James Park Clinical
More informationMolecular Biomarkers in the Characterization & Treatment of Colorectal Carcinoma
Molecular Biomarkers in the Characterization & Treatment of Colorectal Carcinoma Andrew C. Nelson, M.D., Ph.D. Divisions of Anatomic & Molecular Pathology Department of Laboratory Medicine & Pathology
More informationCHEMOTHERAPY FOR COLON CANCER OUTLINE OF TODAY S TALK. Colon Cancer Epidemiology 11/6/2012 GATRA/GCCR FALL CONFERENCE NOVEMBER 14 16, 2012
CHEMOTHERAPY FOR COLON CANCER JONATHAN C. BENDER,MD MEDICAL DIRECTOR OF PIEDMONT FAYETTE CANCER CENTER OUTLINE OF TODAY S TALK 1. Overview of Colon Cancer in the US 2. Colon Cancer staging and risks of
More informationCurrent and future applications of Molecular Pathology. Kathy Walsh Clinical Scientist NHS Lothian
Current and future applications of Molecular Pathology Kathy Walsh Clinical Scientist NHS Lothian Molecular Pathology in Solid tumours Cancer type Genes tested Purpose Associated treatments Non small cell
More informationThe molecular genetics of colorectal cancer
1 Department of Gastroenterology, North Middlesex University Hospital, London, UK 2 Institute of Molecular Genetics, Cardiff University 3 Department of Gastroenterology, Queen s Hospital Romford, London,
More informationA Brief Overview of Screening and Management of Colorectal Cancer
A Brief Overview of Screening and Management of Colorectal Cancer Gentry King MD Assistant Professor Hematology and Medical Oncology University of Colorado Disclosures Nothing to disclose Objectives Review
More informationHeavilyTreated mcrc..whats next?
ESMO Preceptorship Programme Gastrointestinal Cancer 20-22 October 2016,Singapore Dr Surendra Pal Chaudhary Dept of Medical Oncology Dr BR Ambedkar Instituite Rotary Cancer Hospital All India Institute
More informationAssessment of Universal Mismatch repair (MMR) or Microsatellite Instability (MSI) testing in colorectal cancers.
Assessment of Universal Mismatch repair (MMR) or Microsatellite Instability (MSI) testing in colorectal cancers. Soheila Hamidpour MD, Madhusudhana S MD. MMR deficient colorectal tumors can be present
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationImmunotherapy on the Horizon
Immunotherapy on the Horizon Andrew L. Coveler Assistant Professor of Medicine, Division of Oncology University of Washington Assistant Member Fred Hutchinson Cancer Research Center Image: NASA.gov 1 2
More informationAdjuvant treatment Colon Cancer
ESMO Preceptorship Colorectal Cancer, October 2016 Singapore Adjuvant treatment Colon Cancer Claus-Henning Köhne University Clinic for Onkology und Haematology Oldenburg, Germany Aim of the lecture Adjuvant
More informationResource impact report: Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27)
Putting NICE guidance into practice Resource impact report: Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27) Published: February 2017 Summary Molecular testing strategies
More informationTargets & therapies for colorectal cancer
Targets & therapies for colorectal cancer Jan Schellens Werkgroep "MOLECULAIRE DIAGNOSTIEK IN DE PATHOLOGIE 31-01-2014 Current treatment options for advanced colorectal cancer (CRC) First line: - CAPOX
More informationA Review from the Genetic Counselor s Perspective
: A Review from the Genetic Counselor s Perspective Erin Sutcliffe, MS, CGC Certified Genetic Counselor Cancer Risk Evaluation Program INTRODUCTION Errors in base pair matching that occur during DNA replication,
More informationClinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D.
Clinical Biomarker in Kidney Cancer Maria Nirvana Formiga, M.D., Ph.D. Disclosures I am on the Speaker s Bureau with Pfizer and Bayer Clinical trials of BMS and Pfizer Kidney Cancer 70% new cases in developed
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationProgress towards an individualized approach to therapy: colorectal cancer
Progress towards an individualized approach to therapy: colorectal cancer Alan P. Venook, M.D. University of California, SF GIST: PET change after 4 weeks imatinib Multiple liver and upper abdominal 18
More informationClinical, Pathologic and Molecular Updates
Colorectal Cancer: Clinical, Pathologic and Molecular Updates Joanna A. Gibson, M.D./Ph.D. Yale University School of Medicine/Yale New Haven Hospital, Department of Pathology Gastrointestinal, Pancreaticobiliary
More informationCOLON CANCER PROFILE 2012} Cancer Outcomes Analysis Report. The Institute for. Cancer Care
COLON CANCER PROFILE 2012} Cancer Outcomes Analysis Report The Institute for Cancer Care FACT} People with a first-degree relative (parent, sibling, or children) who has colon cancer are between two and
More informationColorectal Neoplasia. Dr. Smita Devani MBChB, MRCP. Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi
Colorectal Neoplasia Dr. Smita Devani MBChB, MRCP Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi Case History BT, 69yr male Caucasian History of rectal bleeding No change
More informationManagement of higher risk of colorectal cancer. Huw Thomas
Management of higher risk of colorectal cancer Huw Thomas Colorectal Cancer 41,000 new cases pa in UK 16,000 deaths pa 60% 5 year survival Adenoma-carcinoma sequence (Morson) Survival vs stage (Dukes)
More informationTHE ROLE OF PREDICTIVE AND PROGNOSTIC MARKERS IN COLORECTAL CANCER
THE ROLE OF PREDICTIVE AND PROGNOSTIC MARKERS IN COLORECTAL CANCER Cathy Eng, M.D., F.A.C.P. Associate Professor Associate Medical Director, Colorectal Center Dept of GI Medical Oncology November 5, 2010
More informationWHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER?
CANCER STAGING TNM and prognosis in CRC WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER? Alessandro Lugli, MD Institute of Pathology University of Bern Switzerland Maastricht, June 19
More informationLynch Syndrome Screening for Endometrial Cancer: Basic Concepts 1/16/2017
1 Hi, my name is Sarah Kerr. I m a pathologist at Mayo Clinic, where I participate in our high volume Lynch syndrome tumor testing practice. Today I hope to cover some of the basics needed to understand
More informationLOINC. Clinical information. RCPA code. Record if different to report header Operating surgeon name and contact details. Absent.
Complete as narrative or use the structured format below 55752-0 17.02.28593 Clinical information 22027-7 17.02.30001 Record if different to report header Operating surgeon name and contact details 52101004
More informationCTC in clinical studies: Latest reports on GI cancers
CTC in clinical studies: Latest reports on GI cancers François-Clément Bidard, MD PhD GI cancers are characterized by Multimodal treatment strategies Treatments are adapted to tumor burden & prognosis
More informationJY Douillard MD, PhD Professor of Medical Oncology
ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Vienna 26-27 Program October 2015 Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer
More information